Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Current Deferred Revenue (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Current Deferred Revenue for 7 consecutive years, with $50.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Deferred Revenue fell 14.62% year-over-year to $50.3 million, compared with a TTM value of $50.3 million through Dec 2025, down 14.62%, and an annual FY2025 reading of $50.3 million, down 14.62% over the prior year.
  • Current Deferred Revenue was $50.3 million for Q4 2025 at Avidity Biosciences, up from $19.1 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $69.3 million in Q4 2023 and bottomed at $2.0 million in Q3 2023.
  • Average Current Deferred Revenue over 5 years is $27.9 million, with a median of $8.6 million recorded in 2021.
  • The sharpest move saw Current Deferred Revenue soared 3046.39% in 2024, then crashed 69.12% in 2025.
  • Year by year, Current Deferred Revenue stood at $11.1 million in 2021, then tumbled by 44.41% to $6.2 million in 2022, then surged by 1021.67% to $69.3 million in 2023, then fell by 14.89% to $58.9 million in 2024, then decreased by 14.62% to $50.3 million in 2025.
  • Business Quant data shows Current Deferred Revenue for RNA at $50.3 million in Q4 2025, $19.1 million in Q3 2025, and $53.5 million in Q2 2025.